



Metabolix Senior Scientist Dr. Rajendra K. Krishnaswamy Receives Society of Plastics Engineers's Lifetime Achievement Award

Krishnaswamy Recognized for Significant Contributions to the Polymers Industry at ANTEC 2011

CAMBRIDGE, Mass., May 24, 2011 – [Metabolix](#) (NASDAQ: MBLX), a bioscience company focused on developing clean, sustainable solutions for plastics, chemicals and energy, today announced that Senior Scientist Dr. Rajendra K. Krishnaswamy was honored by the [Society of Plastics Engineers](#) (SPE) with a lifetime achievement award for his considerable contributions to the polymers industry. The Research/Engineering Technology Award for lifetime achievement in plastics research/engineering was presented to Dr. Krishnaswamy at [ANTEC 2011](#) in Boston, Mass.

“It is a tremendous honor to receive one of SPE’s lifetime achievement awards, which would not be possible without the support of, encouragement from and collaboration with the Metabolix team,” said Dr. Krishnaswamy. “I am looking forward to continuing my association with the Metabolix team, creating new, innovative advances that will benefit the entire plastics industry.”

Dr. Krishnaswamy leads the development of a family of biobased and biodegradable polymers for film and blow-molding applications at Metabolix. His approach to product development combines a theoretical understanding of polymer rheology with traditional scientific methods – from design-of-experiments (DOE) approaches to new product development. A number of Dr. Krishnaswamy’s innovations have led to advancements in Mirel™, a commercialized bioplastics offering from Telles, a joint venture between Metabolix and Archer Daniels Midland Company.

“We’ve always been incredibly proud of Dr. Krishnaswamy’s achievements in the polymer space and are very fortunate to have him on our team,” said Rick Eno, CEO of Metabolix. “Under Dr. Krishnaswamy’s guidance, his team developed a unique patented formulation of new PHA biopolymers, thus playing an integral role in Metabolix’s ability to provide the market with more sustainable bioplastic materials. SPE’s lifetime achievement award reflects Dr. Krishnaswamy’s many contributions to the research and development of biobased and biodegradable plastics.”

Prior to joining the company in 2006, Dr. Krishnaswamy spent nine years in the polymer science group at Chevron Phillips Chemical Company. He currently serves on the editorial boards of the *Journal of Plastic Film and Sheeting* and the *Encyclopedia of Polymer Science and Technology*. Additionally, he serves on the Engineering Properties and Structure Division (EPSDIV) and bioplastics boards of SPE, as well as the materials science board of the American Institute of Chemical Engineers (AIChE). To date, Dr. Krishnaswamy has co-authored more than 40 peer-

reviewed papers and over 25 patents and patent applications, and has been an invited speaker at many conferences and universities worldwide.

About Metabolix

Founded in 1992, Metabolix, Inc. is an innovation-driven bioscience company focused on providing sustainable solutions for the world's needs for plastics, chemicals and energy. The Company is taking a systems approach, from gene to end product, integrating sophisticated biotechnology with advanced industrial practice. Metabolix is now developing and commercializing Mirel™, a family of high-performance bioplastics which are biobased and biodegradable alternatives to many petroleum-based plastics, through Telles, a joint venture between Metabolix and Archer Daniels Midland Company. Metabolix is also developing biosourced industrial chemicals and a proprietary platform technology for co-producing plastics, chemicals and energy, from crops such as switchgrass, oilseeds and sugarcane. For more information, please visit www.metabolix.com. (MBLX-G)

Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding expectations for advances in Metabolix technology, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated and are detailed in Metabolix's filings with the Securities and Exchange Commission. Metabolix assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.

Contacts

Media: Keith Giannini or Jen Barlow, Schwartz Communications, (781) 684-0770
metabolix@schwartzcomm.com

Investors: James Palczynski, ICR, (203) 682-8229
james.palczynski@icrinc.com

###